AIMS: To characterise the detailed phenotype of "cone dystrophy with supernormal rod ERG" in a case series of 10 patients. METHODS: 10 affected patients were examined clinically and underwent colour fundus photography, with nine undergoing detailed electrophysiological testing. Five patients were assessed further with fundus autofluorescence (AF) imaging, automated photopic and dark adapted perimetry, and dark adaptometry. Detailed colour vision assessment was performed in six subjects. Blood samples were taken from four patients for DNA extraction and mutation screening of NR2E3 was undertaken. RESULTS: The onset of symptoms was in the first and second decades of life. Subjects presented with reduced central vision and marked photophobia. All individuals were myopic and colour vision testing revealed severely reduced colour discrimination predominantly along the red-green axes; tritan colour vision was relatively well preserved. Nyctalopia is a later feature of the disorder. Funduscopy and AF imaging revealed a range of macular appearances. There was electrophysiological evidence of marked macular dysfunction, reduced and delayed cone responses, and supernormal and delayed rod responses. Photopic and dark adapted perimetry revealed central scotomata with widespread peripheral sensitivity loss. No disease causing sequence variants in NR2E3 were identified. CONCLUSIONS: The largest case series to date has been described of the clinical, psychophysical and electrophysiological characteristics of this unusual cone dystrophy with supernormal rod responses. Electrophysiological data were consistent with a post-phototransduction, but pre-inner nuclear layer, site of dysfunction. While the definitive diagnosis can only be made with electrophysiological testing, several characteristics that may increase suspicion of this diagnosis are presented.
AIMS: To characterise the detailed phenotype of "cone dystrophy with supernormal rod ERG" in a case series of 10 patients. METHODS: 10 affected patients were examined clinically and underwent colour fundus photography, with nine undergoing detailed electrophysiological testing. Five patients were assessed further with fundus autofluorescence (AF) imaging, automated photopic and dark adapted perimetry, and dark adaptometry. Detailed colour vision assessment was performed in six subjects. Blood samples were taken from four patients for DNA extraction and mutation screening of NR2E3 was undertaken. RESULTS: The onset of symptoms was in the first and second decades of life. Subjects presented with reduced central vision and marked photophobia. All individuals were myopic and colour vision testing revealed severely reduced colour discrimination predominantly along the red-green axes; tritan colour vision was relatively well preserved. Nyctalopia is a later feature of the disorder. Funduscopy and AF imaging revealed a range of macular appearances. There was electrophysiological evidence of marked macular dysfunction, reduced and delayed cone responses, and supernormal and delayed rod responses. Photopic and dark adapted perimetry revealed central scotomata with widespread peripheral sensitivity loss. No disease causing sequence variants in NR2E3 were identified. CONCLUSIONS: The largest case series to date has been described of the clinical, psychophysical and electrophysiological characteristics of this unusual cone dystrophy with supernormal rod responses. Electrophysiological data were consistent with a post-phototransduction, but pre-inner nuclear layer, site of dysfunction. While the definitive diagnosis can only be made with electrophysiological testing, several characteristics that may increase suspicion of this diagnosis are presented.
Authors: S G Jacobson; W J Voigt; J M Parel; P P Apáthy; L Nghiem-Phu; S W Myers; V M Patella Journal: Ophthalmology Date: 1986-12 Impact factor: 12.079
Authors: Tamara Lee Lenis; Elona Dhrami-Gavazi; Winston Lee; Sri Krishna Mukkamala; Mirela Raluca Tabacaru; Lawrence Yannuzzi; Peter Gouras; Stephen H Tsang Journal: JAMA Ophthalmol Date: 2013-11 Impact factor: 7.389
Authors: Frederick T Collison; Jason C Park; Gerald A Fishman; Edwin M Stone; J Jason McAnany Journal: Doc Ophthalmol Date: 2019-03-29 Impact factor: 2.379
Authors: Huimin Wu; Jill A Cowing; Michel Michaelides; Susan E Wilkie; Glen Jeffery; Sharon A Jenkins; Viktoria Mester; Alan C Bird; Anthony G Robson; Graham E Holder; Anthony T Moore; David M Hunt; Andrew R Webster Journal: Am J Hum Genet Date: 2006-07-24 Impact factor: 11.025
Authors: Nan-Kai Wang; Chai Lin Chou; Luiz H Lima; Wener Cella; Joaquin Tosi; Lawrence A Yannuzzi; Stephen H Tsang Journal: Doc Ophthalmol Date: 2009-04-02 Impact factor: 2.379
Authors: Michalis Georgiou; Anthony G Robson; Kaoru Fujinami; Shaun M Leo; Ajoy Vincent; Fadi Nasser; Thales Antônio Cabral De Guimarães; Samer Khateb; Nikolas Pontikos; Yu Fujinami-Yokokawa; Xiao Liu; Kazushige Tsunoda; Takaaki Hayashi; Mauricio E Vargas; Alberta A H J Thiadens; Emanuel R de Carvalho; Xuan-Thanh-An Nguyen; Gavin Arno; Omar A Mahroo; Maria Inmaculada Martin-Merida; Belen Jimenez-Rolando; Gema Gordo; Ester Carreño; Ayuso Carmen; Dror Sharon; Susanne Kohl; Rachel M Huckfeldt; Bernd Wissinger; Camiel J F Boon; Eyal Banin; Mark E Pennesi; Arif O Khan; Andrew R Webster; Eberhart Zrenner; Elise Héon; Michel Michaelides Journal: Am J Ophthalmol Date: 2020-12-11 Impact factor: 5.258
Authors: Anthony G Robson; Michel Michaelides; Zubin Saihan; Alan C Bird; Andrew R Webster; Anthony T Moore; Fred W Fitzke; Graham E Holder Journal: Doc Ophthalmol Date: 2007-11-06 Impact factor: 2.379